financetom
Business
financetom
/
Business
/
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On
Jul 8, 2025 9:18 PM

Calidi Biotherapeutics Inc ( CLDI ). stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price increased by $0.095, reaching $0.34. The company’s stock had closed at $0.24 on the same day.

What Happened: The stock’s after-hours surge comes on the heels of a development in the healthcare sector. Calidi Biotherapeutics ( CLDI ) has been making headlines for its innovative approaches to cancer treatment. 

On Tuesday, it was reported that 12 health care stocks, including Calidi Biotherapeutics ( CLDI ), were experiencing movement in the after-market session.

See Also: Cramer Says This Missile Stock Is ‘Making A Lot Of People A Lot Of Money’

In May, the company reported first-quarter loss per share of $0.18, which missed the $0.15 estimate.

Why It Matters: The after-hours surge in Calidi Biotherapeutics’ stock price is indicative of investor confidence in the company’s future prospects. The company’s innovative approach to cancer treatment, as evidenced by the selection of IL15 superagonist, has been a key driver of investor interest.

Amidst a backdrop of developments in the healthcare sector, such as Mustang Bio ( MBIO ) Inc.‘s stock exploding by 260% after the FDA granted Orphan Drug Designation to its cell therapy candidate, MB-101, it suggests investors are closely watching the biotech industry for potential opportunities.

Price Action: CLDI surged 39.47% during regular trading and jumped another 68.99% after hours on Tuesday, according to Benzinga Pro data.

Benzinga Edge Stock Rankings shows Calidi Biotherapeutics ( CLDI ) with a Momentum score of 1.63. Here is how the stock fares on other parameters.

Read Next: Tesla Tanks $68 Billion As Elon Musk Unveils 'America Party'—Investors Rattle Over Political Pivot, Trump Backlash Adds Fuel

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lilly to acquire Orna Therapeutics to advance cell therapies
Lilly to acquire Orna Therapeutics to advance cell therapies
Mar 11, 2026
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Orna Therapeutics, Inc., a biotechnology company dedicated...
Dynatrace Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Raises 2026 Guidance
Dynatrace Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Raises 2026 Guidance
Mar 11, 2026
06:58 AM EST, 02/09/2026 (MT Newswires) -- Dynatrace ( DT ) reported fiscal Q3 non-GAAP net income Monday of $0.44 per diluted share, up from $0.37 a year earlier. Analysts polled by FactSet expected $0.41. Revenue for the quarter ended Dec. 31 was $515.5 million, compared with $436.2 million a year earlier. Analysts surveyed by FactSet expected $505.8 million. For...
Becton Dickinson Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Shares Down Pre-Bell
Becton Dickinson Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Shares Down Pre-Bell
Mar 11, 2026
06:58 AM EST, 02/09/2026 (MT Newswires) -- Becton Dickinson ( BDX ) reported fiscal Q1 adjusted earnings Monday of $2.91 per diluted share, down from $3.43 a year earlier. Analysts polled by FactSet expected $2.81. Revenue for the quarter ended Dec. 31 was $5.25 billion, compared with $5.17 billion a year earlier. Analysts polled by FactSet expected $5.15 billion. The...
JOSS Realty REIT, Inc. Announces Launch of Initial Public Offering
JOSS Realty REIT, Inc. Announces Launch of Initial Public Offering
Mar 11, 2026
NEW YORK--(BUSINESS WIRE)-- JOSS Realty REIT, Inc. (JOSS or the Company) today announced the launch of its initial public offering of 3,000,000 shares of common stock. The initial public offering price is expected to be between $4 and $6 per share. JOSS expects to grant the underwriters a 45-day option to purchase up to an additional 450,000 shares of its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved